Novartis has achieved a key clinical milestone with delpacibart braxlosiran FSHD, as its FORTITUDE biomarker cohort successfully met the primary endpoint by substantially suppressing DUX4-driven gene expression and reducing muscle damage markers in patients with facioscapulohumeral muscular dystr...

Athlete risk stratification now integrates epidemiological evidence, explainable artificial intelligence, and mechanistic cardiac models to better protect young competitors. This convergence offers a path to distinguish healthy athletic remodeling from hidden substrates that can trigger fatal arr...

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...

The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...

Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...